Cargando…

Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection

Vascular adhesion protein-1 (VAP-1) is a multifunction protein. While membrane-bound VAP-1 is an adhesion protein, soluble VAP-1 catalyzes the deamination of primary amines through its semicarbazide-sensitive amino oxidase (SSAO) activity. VAP-1 supports the transmigration of leukocytes and increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraemer, Marcel, Krawczyk, Marcin, Noor, Fozia, Grünhage, Frank, Lammert, Frank, Schneider, Jochen G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352124/
https://www.ncbi.nlm.nih.gov/pubmed/30658395
http://dx.doi.org/10.3390/jcm8010103
_version_ 1783390756120035328
author Kraemer, Marcel
Krawczyk, Marcin
Noor, Fozia
Grünhage, Frank
Lammert, Frank
Schneider, Jochen G.
author_facet Kraemer, Marcel
Krawczyk, Marcin
Noor, Fozia
Grünhage, Frank
Lammert, Frank
Schneider, Jochen G.
author_sort Kraemer, Marcel
collection PubMed
description Vascular adhesion protein-1 (VAP-1) is a multifunction protein. While membrane-bound VAP-1 is an adhesion protein, soluble VAP-1 catalyzes the deamination of primary amines through its semicarbazide-sensitive amino oxidase (SSAO) activity. VAP-1 supports the transmigration of leukocytes and increases oxidative stress. In chronic liver diseases, it plays a role in leukocyte infiltration and fibrogenesis. Here, we measured VAP-1 plasma concentration and its SSAO activity in 322 patients with chronic hepatitis C infection and evaluated the association of VAP-1 with fibrosis stages. VAP-1 concentration strongly correlated with liver stiffness and was the second strongest influencing variable after gamma-glutamytransferase (GGT) for liver stiffness in regression analysis. The VAP-1 concentration increased with advancing fibrosis stages and the highest concentrations were found in patients with cirrhosis. According to the receiver operating characteristic (ROC) analysis, a VAP-1 cut-off value of 541 ng/mL predicted histologically confirmed cirrhosis (sensitivity 74%; specificity 72%). SSAO activity correlated only moderately with liver stiffness, showing a relatively small increase in advanced fibrosis. To our knowledge, this is the first study on VAP-1 in chronic hepatitis C infection showing its association with progressive fibrosis. In conclusion, VAP-1 plasma concentration, rather than its SSAO activity, may represent a non-invasive biomarker for monitoring fibrogenesis in patients with chronic hepatitis C infection.
format Online
Article
Text
id pubmed-6352124
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63521242019-02-01 Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection Kraemer, Marcel Krawczyk, Marcin Noor, Fozia Grünhage, Frank Lammert, Frank Schneider, Jochen G. J Clin Med Article Vascular adhesion protein-1 (VAP-1) is a multifunction protein. While membrane-bound VAP-1 is an adhesion protein, soluble VAP-1 catalyzes the deamination of primary amines through its semicarbazide-sensitive amino oxidase (SSAO) activity. VAP-1 supports the transmigration of leukocytes and increases oxidative stress. In chronic liver diseases, it plays a role in leukocyte infiltration and fibrogenesis. Here, we measured VAP-1 plasma concentration and its SSAO activity in 322 patients with chronic hepatitis C infection and evaluated the association of VAP-1 with fibrosis stages. VAP-1 concentration strongly correlated with liver stiffness and was the second strongest influencing variable after gamma-glutamytransferase (GGT) for liver stiffness in regression analysis. The VAP-1 concentration increased with advancing fibrosis stages and the highest concentrations were found in patients with cirrhosis. According to the receiver operating characteristic (ROC) analysis, a VAP-1 cut-off value of 541 ng/mL predicted histologically confirmed cirrhosis (sensitivity 74%; specificity 72%). SSAO activity correlated only moderately with liver stiffness, showing a relatively small increase in advanced fibrosis. To our knowledge, this is the first study on VAP-1 in chronic hepatitis C infection showing its association with progressive fibrosis. In conclusion, VAP-1 plasma concentration, rather than its SSAO activity, may represent a non-invasive biomarker for monitoring fibrogenesis in patients with chronic hepatitis C infection. MDPI 2019-01-17 /pmc/articles/PMC6352124/ /pubmed/30658395 http://dx.doi.org/10.3390/jcm8010103 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kraemer, Marcel
Krawczyk, Marcin
Noor, Fozia
Grünhage, Frank
Lammert, Frank
Schneider, Jochen G.
Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection
title Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection
title_full Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection
title_fullStr Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection
title_full_unstemmed Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection
title_short Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection
title_sort increased circulating vap-1 levels are associated with liver fibrosis in chronic hepatitis c infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352124/
https://www.ncbi.nlm.nih.gov/pubmed/30658395
http://dx.doi.org/10.3390/jcm8010103
work_keys_str_mv AT kraemermarcel increasedcirculatingvap1levelsareassociatedwithliverfibrosisinchronichepatitiscinfection
AT krawczykmarcin increasedcirculatingvap1levelsareassociatedwithliverfibrosisinchronichepatitiscinfection
AT noorfozia increasedcirculatingvap1levelsareassociatedwithliverfibrosisinchronichepatitiscinfection
AT grunhagefrank increasedcirculatingvap1levelsareassociatedwithliverfibrosisinchronichepatitiscinfection
AT lammertfrank increasedcirculatingvap1levelsareassociatedwithliverfibrosisinchronichepatitiscinfection
AT schneiderjocheng increasedcirculatingvap1levelsareassociatedwithliverfibrosisinchronichepatitiscinfection